WO2024052820 - UPADACITINIB FORMULATION
National phase entry:
Publication Number
WO/2024/052820
Publication Date
14.03.2024
International Application No.
PCT/IB2023/058794
International Filing Date
06.09.2023
Title **
[English]
UPADACITINIB FORMULATION
[French]
FORMULATION D'UPADACITINIB
Applicants **
INTAS PHARMACEUTICALS LTD.
Inventors
PATIL, Rahul Sudhakar
PATEL, Sandip Kumar Manubhai
JAMLOKI, Ashutosh
SEHGAL, Ashish
Priority Data
202221051592
09.09.2022
IN
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
IP India
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 1954 | |
| EPO | Filing, Examination, Granting | 11600 | |
| Japan | Filing, Examination, Granting | 1961 | |
| South Korea | Filing, Examination, Granting | 1654 | |
| USA | Filing, Examination, Granting | 5340 |
Total:
22,509
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
The present invention is related to pharmaceutical composition of upadacitinib comprising upadacitinib or its pharmaceutically acceptable salt thereof, release controlling polymer, pH modifier and one or more pharmaceutical acceptable excipient; wherein the release controlling polymer is hydrophobic polymer.[French]
La présente invention concerne une composition pharmaceutique d'upadacitinib comprenant de l'upadacitinib ou son sel pharmaceutiquement acceptable, un polymère de contrôle de libération, un modificateur de pH et un ou plusieurs excipients pharmaceutiques acceptables ; le polymère de contrôle de libération étant un polymère hydrophobe.